LONDON, March 10, 2017 /PRNewswire/ --

Cancer, Cardiovascular, CNS, Other Disease Areas and Non-Therapeutic Applications

The global stem cell technologies and applications market is expected to grow at a CAGR of 13.4% in the first half of the forecast period and CAGR of 10.5% in the second half of the forecast period. The market is expected to grow at a CAGR of 11.7% from 2016 to 2027. The market is estimated at $10,751 million in 2016 and $17,768 million in 2020.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 257-page report you will receive 114 charts - all unavailable elsewhere.

The 257-page report provides clear detailed insight into the global stem cell technologies and applications market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope
• Global Stem Cell Technologies and Applications Market forecasts from 2017-2027

• Global Stem Cell Technologies and Applications submarket forecasts from 2017-2027:
- Cancer treatment
- Cardiovascular therapy
- CNS
- Other therapies
- Non-therapeutic applications

• Individual revenue forecast to 2027 for selected top products:
- MSC-100-IV (Mesoblast)
- Hearticellgram-AMI (Pharmicell)
- CardioRel (Reliance Life Sciences)
- Osteocel Plus (NuVasive)
- Trinity Evolution and Elite (Orthofix)
- CARTISTEM (MEDIPOST)

• Analysis of the most promising pipeline therapies in each therapeutic segment

• Discussion on regulatory environments and developments in the US, Japan, Europe and other leading countries

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

• Analysis of what drives and restrains the market

• This study also discusses other influences on that field, including these:
- Haematopoietic stem cell transplantation (HSCT)
- Embryonic stem cells (ESCs), induced pluripotent adult (IPSCs) and parthenogenetic cells
- Uses for umbilical cord blood and related technologies, including cellular and blood banking
- Agents for osteogenesis and treating autoimmune conditions
- Applications in cell-based assays, diagnostics and drug development.

Visiongain's study is intended for anyone requiring commercial analyses for the Global Stem Cell Technologies and Applications Market. You find data, trends and predictions.

Buy our report today Global Stem Cell Technologies and Applications Market 2017-2027: Cancer, Cardiovascular, CNS, Other Disease Areas and Non-Therapeutic Applications.

To request a report overview of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44-(0)-20-7336-6100

Or click on: https://www.visiongain.com/Report/1816/Global-Stem-Cell-Technologies-and-Applications-Market-2017-2027

List of Companies and Organizations Mentioned in the Report 

Aastrom Biosciences

Advanced Cell Technology

Alder Biopharmaceuticals

Alkems

AllCells

Allergan

AlloSource

American Academy of Neurology

American Academy of Pediatrics (AAP)

American Neurological Associates Annual Meeting

American Society of Blood and Marrow Transplantation.

Americas Committee for Treatment and Research in Multiple Sclerosis

Americord

Amgen

Angiocrine Bioscience

Anterogen

Arteriocyte

Associated Press

Asterias Biotherapeutics

Athersys

Auriga Ventures

Axiogenesis

Baxter Healthcare

BaYi Brain Hospital

BioCardia

BioE

BioEden

Biogenea-Cellgenea

Bioheart, Inc

Biologic Therapies

BioMet Orthopedics

BioTime

BioTime Asia

Blackstone Medical

Bluebird Bio

BMJ (The British Medical Journal)

Boston Children's Hospital

BrainStorm Cell Therapeutics

Caladrius Biosciences

California Institute for Regenerative Medicine (CIRM)

Calimmune

Capricor

Cardio3

Caribou

Carolinas Cord Blood Bank (CCBB)

Casey Eye Institute

Cedars-Sinai Heart Institute

Cell Cure Neurosciences

Cell Therapy Catapult

CellCentric

Cellectis

Cellerant Therapeutics

Cellerix

CELLTREE

Cellular Biomedicine Group (CBMG)

Cellular Dynamics International

Center for International Blood and Marrow Transplant Research (CIBMTR)

Centers for Medicare & Medicaid Services

Cephalon

Cesca Therapeutics

Ceylad

Cha General Hospital

China Cord Blood Corporation

China Food and Drug Administration (CFDA)

Chinese Academy of Sciences

Chinese Ministry of Health

Chinese Ministry of Science and Technology

CJ CheilJedang

Clal Biotechnologies Industries

Cleveland Biolabs

Clinicaltrials.gov

ClinImmune Labs

Cochrane

Cognate BioServices

Committee for Medicinal Products for Human Use (CHMP)

Consortium of Multiple Sclerosis Centers

Cook General BioTechnology

Cord Blood America

Cord Blood Registry Systems

Cordlife Group

CRISPR Therapeutics

Cryo-Cell International

CryoCord

Cryonix CJSC

Cryo-Save

CXR Biosciences

Cytori Therapeutics

Data Safety Monitoring Board (DSMB)

Denali Ventures

Dendreon

Dong-A Pharmaceuticals Co

Drugs and Cell Therapies in Haematology (Journal)

Duke University School of Medicine

Elbit Imaging

Elbit Medical Technologies

Eli Lilly

Elsevier

EMA

EMA Committee for Orphan Medicinal Products

EpiStem

ESI Bio

European Court of Human Rights

European Court of Justice

European Group for Blood and Marrow Transplantation (EBMT)

European Haematology Association

EuroStemCell

Fate Therapeutics

FDS Pharma

Federal D.C. Court of Appeals

Fondazione Centro San Raffaele

Fondazione Telethon

Forbion Capital Partners

Forticell Bioscience

Gamida Cell

Gemabank

Gene Therapy Advisory Committee

Genetico

Genetrix Group

Geron

Gilead

GlobalStem

Globocan

GSK

Harvard Apparatus Regenerative Technology

Harvard Business School

Harvard Stem Cell Institute

Harvard University

Howard Hughes Medical Institute

Human Fertilisation and Embryology Authority (HFEA)

Human Stem Cells Institute

Human Tissue Authority

ImmunoCellular Therapeutics

Immunovative Therapies

Indian Department of Biotechnology

Insception Biosciences

Intellia Therapeutics

IntelliCell Biosciences

International Society for Stem Cell Research (ISSCR)

International Stem Cell Corporation (ISCO)

International Stemcell Services

IPS Academia Japan

Isar Medical Centre

Israel Healthcare Venture

Israel Stem Cell Society

Japan Institute of Biomedical Research.

Japan's Ministry of Economy, Trade and Industry (METI)

Japanese Health Ministry

Japanese Ministry of Labour and Welfare (MHLW)

Japanese Pharmaceuticals and Medical Devices Agency

JCR Pharmaceuticals

JingYuan Bio

Johnson & Johnson

Karolinska Institute

Korean Food and Drug Administration

Korean MFDS (Ministry of Food and Drug Safety)

Lifebank Cryogenics

LifebankUSA

LifeMap Sciences

LifeMap Solutions

LifeSouth Community Blood Centers Inc

Lonza

Massachusetts General Hospital

Maxcyte

Mayo Clinic

McMaster University

MedCell Bioscience

MEDIPOST

Medistem Panama

Medtronic

Mesoblast

Miltenyi Biotec

Musculoskeletal Transplant Foundation (MTF)

National Dental Pulp Laboratory

Nature (journal)

Nature Biotechnology (Journal)

NeoStem

Neuralstem

New England Journal of Medicine

New York Blood Center

New York Blood Center's Milstein National Cord Blood Program (NCBP)

New York Heart Association

NHS Blood and Transplant Authority

Northwestern University

Novartis

Novartis Research Foundation

NurOwn

Nuvasive

Ocata Therapeutics

OncoCyte

Opexa Therapeutics

Oregon Health and Science University

OrLife Bio

Orthofix

Osiris Therapeutics

Pahrump Valley Times

Pfizer

Pharmicell

Pharmsynthez

Plasticell

Pluristem

Polyphor

Prix Galien

Q Therapeutics

Queen Mary University of London

Quest Biomedical

ReCyte

Regenerative Sciences

Regenerex

Regeneron

Regeneus

Reliance Group

Reliance Life Sciences

ReNeuron

RepliCel Life Sciences

Reprobank

ReproCELL

RIKEN Center for Developmental Biology

Roche

Roslin Cellab

RTI Biologics

RTI Surgical

RUSNANO Corporation

RVC OJSC

SanBio

Sangamo BioSciences

Sanofi

Science (journal)

S-Evans Biosciences

Spinesmith Partners

SSM Cardinal Glennon Children's Medical Center

Stem Cell Bank

Stemcell Technologies  

StemCells

StemCore

StemCyte

Stemedica Cell Technologies

StemGen

Stemina Biomarker Discovery

SynBio

TAP Biosystems (Sartorius Stedim Biotech

Tel Aviv University

Teva

The Committee for Advanced Therapies (CAT)

The European Commission

The Lancet

The London Project to Cure Blindness

The Marcus Foundation

The Zon Laboratory

Therapeutic Goods Administration

TiGenix

Tong Yuan Stem Cell

TrakCel

Translational Biosciences

U.S. Stem Cell, Inc

UCL Business PLC

UCL Institute of Ophthalmology

UCLA

UK Care Quality Commission

UK Department of Health

UK Department of Health and the Medical Research Council

UK Home Office

UK Medicines and Healthcare Products Regulatory Agency (MHRA)

UK National Institute for Health Research

UK Regenerative Medicine Platform

uniQure

United Nation's Department of Economic and Social Affairs

University of California

University of Colorado Anschutz Medical Campus (AMC)

University of Colorado Cord Blood Bank

University of Kyoto

University of Massachusetts

University of Washington

University of Western Ontario

University of Wisconsin Alumni Research Foundation

US Congress

US District Court for the District of Columbia

US FDA

US National Cord Blood Program

US National Institute of Allergy and Infectious Diseases (NIAID)

US National Institute of Health (NIH)

US National Marrow Donor Program

US National Marrow Donor Program (NMDP)

US Patent and Trademark Office

US Supreme Court

Valeant

Vericel Corporation

Vesta Therapeutics

ViaCord

ViaCyte

ViroMed

Vitro Biopharma

WA Optimum Health Care

WHO

Yale University

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

SOURCE Visiongain Ltd